10x Genomics, Inc. (TXG) Intrinsic Value

DCF-based fair value calculation with Bear, Base, and Bull scenarios

Popular:

10x Genomics, Inc. (TXG)

View Full Profile →

Intrinsic Value

DCF Not Suitable for TXG

Revenue ($642M) below $1B threshold — insufficient business scale for DCF.

Alternative Approach:

Use EV/Sales vs. industry peers for growth-stage companies.

Frequently Asked Questions

Is TXG stock undervalued or overvalued?

Insufficient data to compute DCF valuation for TXG. This typically occurs with negative FCF, early-stage companies, or financials where standard DCF models require modification.

What is TXG's intrinsic value?

Unable to calculate intrinsic value. DCF requires positive free cash flow and complete financial data. For banks/REITs, we substitute Net Income or FFO respectively.

How is TXG's fair value calculated?

Standard two-stage DCF with 5-year explicit forecast period and Gordon Growth terminal value. WACC estimated from sector averages and company beta. For TXG, insufficient data prevents full calculation—typically requires 3+ years of positive FCF history.